Sidvim LifeSciences Private Limited

  Content Analysis of imports of Alembic.  General information.  Will drug prices decrease for Medicare recipients? Pharmaceutical industry says no.  Five pharma cybersecurity breaches to know and learn from..  Intellectual Property.  Apixaban -USA, CAFC decision and impact on generic launches.     Analysis of imports of Alembic   In our firm, we analyse development portfolios of many companies based on public domain information such as patent application filings and import-export database etc. This week we chose Alembic. There are several entries in the database and to cover all those in such a small sized newsletter would be an impossible task. Only a few of the entries have been reported here as a gist of our findings. Our conclusions are summarized in the SIDVIM comments column below. Product Name QTY in KG SIDVIM comments BENZENAMINE,4-[(6,7-DIMETHOXY-4-QUINOLINYL) OXY] 1.5 Intermediate for Cabozantinib. MSN and Sun had already filed DMF, Alembic could be the next. Noticing the or

  Contents Analysis of imports of Biophore.  General information.  Aspen Gets Unsolicited Offers for Pharma Ingredient Unit  Facilitating production of APIs.  Intellectual Property.  Inequitable conduct    Analysis of imports of Biophore In our firm we analyze development portfolios of many companies based on public domain information such as patent application filings and import-export database etc. This week we chose Biophore. As per their website information, they have filed over 60 DMFs so far. So, analyzing their imports we tried to understand their development portfolio, the probable stage of their development etc. The glimpse of our analysis is published here.  Product Name Quantity in Kg API SIDVIM comments (S)-(+)-1,2-PROPANEDIOL 10 Dapagliflozin More than 2 dozen DMFs have been filed. Biophore could be one of them. One has to wait till US  and EU launches, but in India Gx launch is possible after Delhi HC decision which we covered on 27 July 2021 5-(2-FLUORO-3-METHOXYPHENYL)-